The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2020 | Update on momelotinib for myelofibrosis
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, updates us on the clinical use of momelotinib, a JAK1/JAK2 inhibitor in patients with myelofibrosis, including the results of the SIMPLIFY-1 study (NCT01969838), evaluating momelotinib against ruxolitinib in patients with myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
